Oral Bacteria Hijack a Cancer Sugar Coat to Colonize Colorectal Tumors

An oral bacterium called Fusobacterium nucleatum has a puzzling habit: it shows up in colorectal tumors far more often than it has any business being there, and its presence is associated with worse outcomes for patients. A new study published in June 2026 offers an early-stage explanation for how it gains that foothold, pointing to a sugar-modifying enzyme called ST3GAL1 that colorectal cancer cells produce in abnormally high amounts. The findings are preliminary, but they open a specific molecular door worth watching.

ST3GAL1-driven sialylation creates a bacterial landing pad

ST3GAL1 is a glycosyltransferase, meaning it catalyzes the attachment of sugar molecules to proteins and lipids on the cell surface. Its specific job is to add sialic acid, a negatively charged sugar, to these surface structures in a modification called sialylation. Colorectal cancer (CRC) tissue is already known to carry unusually high levels of surface sialylation, and ST3GAL1 is abnormally overexpressed in CRC clinical samples, where it also functions as a prognostic marker for poor patient outcomes. Separately, research has shown that ST3GAL1 contributes to the sialylation of adhesion proteins including integrin beta-1 and CD44, structures that stud the outer surface of many cell types. What this new work adds is the connection: those sialic-acid-decorated surface structures appear to serve as preferred attachment sites for F. nucleatum.

The research team, led by Xiao L., Gong T., and colleagues, found that high sialylation levels mediated specifically by ST3GAL1 in CRC are strongly associated with F. nucleatum adhesion. When they knocked down ST3GAL1 expression, bacterial adhesion dropped significantly; when they overexpressed it, adhesion increased. Both effects were confirmed in cell culture and in animal models, giving the finding a degree of experimental credibility beyond a purely correlational observation.

Why this matters for colorectal cancer patients

F. nucleatum is not an ordinary bystander in colorectal tumors. Its abundance is higher in metastatic CRC than in non-metastatic CRC, and its presence inside tumors has been linked to chemoresistance, shorter survival, and increased relapse rates. A meta-analysis of in vitro co-culture infections described the bacterium as an important microbe-related risk factor for prognosis, partly because it appears to help tumors resist standard chemotherapy regimens.

The study also found that once F. nucleatum adheres, it actively works to entrench itself: the bacterium upregulates H3K27 acetylation, an epigenetic modification that can alter gene expression in host cells to favor colonization. It also enhances expression of ANGPTL4, a protein linked to angiogenesis and tumor progression, suggesting the bacterium does not merely hitch a ride but actively remodels the tumor microenvironment to its advantage.

If ST3GAL1 is the molecular handle that lets F. nucleatum grip cancer cells in the first place, then disrupting that handle could, in principle, reduce bacterial colonization and blunt some of those downstream effects. That is still speculative at this stage, but the logic is coherent.

How the team isolated ST3GAL1's role

The researchers used a combination of knockdown and overexpression experiments to directly test whether ST3GAL1 abundance changes bacterial adhesion. Knockdown means reducing the gene's activity so the cell produces less of the enzyme; overexpression means artificially boosting it so the cell produces more. By toggling ST3GAL1 in both directions and then measuring how much F. nucleatum stuck to the cells, the team could draw a direct line between the enzyme's activity and bacterial adhesion rather than relying on observational data alone.

These experiments were conducted both in vitro (cell culture dishes) and in vivo (animal models), which strengthens the case that the effect is not just a laboratory artifact. The study also draws on the known clinical reality that ST3GAL1 is overexpressed in CRC patient samples, grounding the mechanistic work in a clinically relevant context. Research on sialyltransferases across cancer types has previously identified ST3GAL1 as frequently overexpressed in multiple malignancies and tied to tumor migration and metastasis, so the enzyme's central role here fits a broader pattern.

The study also situates the finding within what is already known about glycosylation and gut health. Dysregulation of glycosylation, the broader family of modifications to which sialylation belongs, can damage the intestinal barrier and disrupt the balance of gut microbes, potentially setting up a cycle in which altered surface chemistry invites pathogenic colonizers and those colonizers then worsen the local environment further.

Open questions about mechanism and clinical translation

Several important caveats apply. The research is investigational: the mechanistic details of exactly how F. nucleatum recognizes and binds sialylated structures on CRC cells are not fully resolved. It remains unclear which specific sialylated molecules on the cancer cell surface are the primary binding targets, and whether blocking ST3GAL1 in a living tumor would meaningfully reduce bacterial load or improve outcomes in patients.

The study also does not address whether the ST3GAL1-sialylation axis is the dominant colonization route or one of several. F. nucleatum has multiple known adhesins, surface proteins it uses to attach to host cells, and the full picture of how it establishes itself in colorectal tissue is likely more complex than a single enzyme interaction.

The ST3GAL1 target and what comes next in CRC research

The practical value of this work lies in identifying ST3GAL1 as a potential point of intervention. Because the enzyme is already flagged as a prognostic marker for poor CRC outcomes and its suppression has previously been shown to reduce CRC cell proliferation and metastasis, it was already on researchers' radar as a therapeutic candidate. This study adds a second reason to pursue it: reducing ST3GAL1 activity might not only slow tumor growth directly but also make tumors less hospitable to a bacterium that actively promotes chemoresistance.

The next steps would logically include identifying the precise sialylated receptors F. nucleatum binds, testing ST3GAL1 inhibition strategies in more complex tumor models, and ultimately determining whether the bacterial adhesion phenotype can be reproduced or reversed in clinical samples. That work is still ahead, but the molecular hypothesis is now considerably more specific than it was.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• Evidence is based on in vitro cell experiments and animal models — human clinical validation has not yet been performed.
• This is a single study and has not been independently replicated.
• Funding was not disclosed by the authors, so potential conflicts of interest cannot be fully assessed.

This study used in vitro cell-line experiments and in vivo animal models to investigate how ST3GAL1-mediated sialylation facilitates Fusobacterium nucleatum adhesion to colorectal cancer cells. The work demonstrates a mechanistic link but does not include a human clinical cohort, so causation in human disease cannot be established. The findings are consistent with prior literature on F. nucleatum enrichment in colorectal cancer but have not yet been independently replicated.

References

1. Li Xiao, Tao Gong, Wanyi Luo, et al. (2026). ST3GAL1 mediates sialylation to promote adhesion of Fusobacterium nucleatum to colorectal cancer cells. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2026.168332
2. Thomas J. Bauer, Erich Gombocz, Markus Wehland, Johann Bauer, Manfred Infanger, Daniela Grimm (2020). Insight in Adhesion Protein Sialylation and Microgravity Dependent Cell Adhesion—An Omics Network Approach. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21051749
3. Katie R. Risoen, Claire A. Shaw, Jeremy Chien, Bart C. Weimer (2025). Fusobacterium nucleatum and Its Impact on Colorectal Cancer Chemoresistance: A Meta-Analysis of In Vitro Co-Culture Infections. Cancers. https://doi.org/10.3390/cancers17193247
4. Marjolaine Hugonnet, Pushpita Singh, Quentin Haas, Stephan von Gunten (2021). The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.799861